Immunovant股价下跌7%，发行价格为5.5亿美元

2025-12-11 18:48

Clinical-stage immunology company Immunovant (IMVT) priced an underwritten offering of its common stock, with anticipated gross proceeds to Immunovant of ~$550M.
Roivant Sciences, the company’s controlling stockholder, has agreed to purchase shares in the offering. All of the shares are to be sold by Immunovant.
The company currently expects that its existing cash and cash equivalents, together with the proceeds from the transaction, will be sufficient to fund its operating expenses and capital expenditures through the potential commercial launch of IMVT-1402 in the Graves’ Disease indication.
Immunovant offered 26.2 million shares of its common stock in the offering at an offering price of $21.00 per share.
The offering is expected to close on or about December 12, 2025.
The stock dropped ~7% on Thursday during pre-market hours of trading.

More on Immunovant